Horse PBMCs

Horse peripheral blood mononuclear cells (PBMCs) are immune response cells that include lymphocytes, monocytes and dendritic cells from horses. Equine PBMCs are widely used in clinical research because they provide a convenient, minimally invasive way to study the immune system and its response to diseases, infections and therapies. Horse PBMCs are useful in understanding various physiological and pathological mechanisms in equines. Lab4Paws collaborates with a network of veterinary clinics to source animal biospecimens complete with patient metadata, indication and treatment.

Advantages of Horse PBMCs
Horse Peripheral Blood Mononuclear Cells (PBMCs) offer several advantages in biomedical research, particularly in the study of specific diseases and formulation of therapeutic interventions.
• Non-Invasive Collection
PBMCs from horses can be collected in a relatively non-invasive method. Due to their large size, horses can be easily sourced for blood through the jugular venipuncture. This is minimally stressful compared to other methods and also allows for repeated sampling.
• Rich Source of Stem Cells
Equine PBMCs are an excellent source of multipotent Mesenchymal Stromal Cells (MSCs). MSCs have displayed great therapeutic potential in regenerative medicine due to their potential to differentiate into different cell types such as osteocytes, adipocytes, and chondrocytes – a trait highly useful for treating musculoskeletal injuries and other disorders.
• Immunomodulatory Properties
PBMCs demonstrate immunomodulatory activities that can help manage inflammatory conditions. PBMCs from horse have been shown to inhibit proliferation of lymphocytes and promote the production of IL-10 and other anti-inflammatory cytokines that aid in inflammation reduction and healing.
• Low Immunogenicity
Equine PBMCs have been found to produce low levels of Major Histocompatibility Complex (MHC), a trait that is advantageous for cell-based therapy development.
• Clinical Potential
Everal studies indicate that horse PBMCs are showing promise in the treatment of osteoarthritis and tendon injuries. PBMC-derived autologous MSC therapy, for instance, have been associated with alleviation of musculoskeletal disorders.

Please contact us at for specific academic pricing.